Release Summary

Mentor Capital, Inc. (MNTR) initiated funding of its GlauCanna venture that is developing medical marijuana treatment for Glaucoma patients. MNTR holds an 80% interest and Dr. Robert Mandelkorn 20%.

Mentor Capital, Inc.